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Breast cancer (BC) in men is rare and genetic predisposition is likely to play a relevant role in its etiology. Inherited mutations
in BRCA1/2 account for about 13% of all cases and additional genes that may contribute to the missing heritability need to be
investigated. In our study, a well-characterized series of 523 male BC (MBC) patients from the Italian multicenter study on
MBC, enriched for non-BRCA1/2 MBC cases, was screened by a multigene custom panel of 50 cancer-associated genes. The
main clinical-pathologic characteristics of MBC in pathogenic variant carriers and non-carriers were also compared. BRCA1/2
pathogenic variants were detected in twenty patients, thus, a total of 503 non-BRCA1/2 MBC patients were examined in our
study. Twenty-seven of the non-BRCA1/2 MBC patients were carriers of germline pathogenic variants in other genes, including
two APC p.Ile1307Lys variant carriers and one MUTYH biallelic variant carrier. PALB2 was the most frequently altered gene
(1.2%) and PALB2 pathogenic variants were significantly associated with high risk of MBC. Non-BRCA1/2 pathogenic variant
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carriers were more likely to have personal (p = 0.0005) and family (p = 0.007) history of cancer. Results of our study support a
central role of PALB2 in MBC susceptibility and show a low impact of CHEK2 on MBC predisposition in the Italian population.
Overall, our data indicate that a multigene testing approach may benefit from appropriately selected patients with implications
for clinical management and counseling of MBC patients and their family members.
What’s new?
While multigene panel testing for breast cancer predisposition has been performed extensively in females, its use in male
breast cancer (MBC) patients has been much more limited, despite a likely role for genetic predisposition in MBC. In this
multicenter study in Italy, panel testing involving 50 cancer-associated genes identified germline pathogenic variants in about
5 percent of BRCA1/2-negative MBC patients. In non-BRCA1/2 MBC, the most frequently mutated genes were PALB2 and ATM,
with PALB2 mutations having a major impact on MBC risk. By comparison, mutations in CHEK2 had little impact on MBC
predisposition in the Italian population.
Introduction
Breast cancer (BC) in men is a rare disease if compared to
BC in women. It represents less than 1% of all BCs and less
than 1% of all cancers in men.1 The annual incidence of male
BC (MBC) is estimated at less than 1 per 100,000 men.2 In
Italy about 500 men were estimated to be diagnosed with BC
in 2017.3 About 20% of MBC patients have family history of
BC and more than 20% develop a second non-breast tumor,4
thus pointing to a relevant role of the genetic component in
MBC susceptibility. Inherited mutations in BRCA1 and, more
commonly, in BRCA2 predispose to MBC and account for
about 13% of all cases.5 There is also some evidence indicat-
ing that CHEK2 and PALB2 germline mutations may increase
MBC risk but, to date, they seem to account for a small pro-
portion of MBC cases.6–8 Thus, many questions still remain
regarding MBC genetic susceptibility and additional genes
that may contribute to the missing heritability need to be
investigated.
Over the last two decades clinical genetic testing has become
widespread as several genes have been associated with increased
risk of BC.9 Next-generation sequencing (NGS) technology has
enabled massive parallel sequencing of multiple cancer suscepti-
bility genes simultaneously in a large number of patients, at
relatively low cost. A broad range of next-generation panels
that evaluate BC- or multiple cancer-associated genes, is now
available from genetic testing laboratories.10–18 Genes fre-
quently included in testing panels comprise high-penetrance
BC genes, such as BRCA1 and BRCA2, moderate/low-penetrance
BC genes, such as PALB2, CHEK2 and ATM, mismatch repair
genes, such as hMLH1 and hMSH2, and genes associated
with hereditary cancer syndromes, such as CDH1, PTEN,
STK11 and TP53.
Results from multigene panel testing indicate that gene
variants associated with BC risk are individually rare and this
has introduced new clinical challenges, as evidence-based risk
estimates for some genes, included in multigene panels, may
not be available and can be significantly modified by the spe-
cific family history of BC.10,19,20
Thus far, multigene panel testing for BC predisposition has
been extensively performed in female BC patients but rarely
in MBC patients.7,8,11 In the present study, we aimed to fur-
ther examine genetic susceptibility to BC in men, analyzing a
large series of Italian MBC patients, enriched for BRCA1/2
mutation negative patients, using a custom multigene panel.
Specific aims of the study were to: -expand the spectrum of
MBC susceptibility genes, -assess the yield of germline patho-
genic variants in BRCA1/2 mutation negative MBC patients
through multigene panel testing, -examine predictors of path-
ogenic variants in non-BRCA1/2 genes.
Materials and Methods
Study population
The present study benefits from a well-characterized series of
MBC cases from 13 Italian Investigator Centers, enrolled in
the frame of the ongoing Italian multicenter study on MBC.21
A total of 523 MBC cases, unselected for age at diagnosis and
family history of cancer, for which enough quantity and good
quality of genomic DNA were available to perform a multi-
gene panel testing, were included in our study. Overall, the
sample set included 443 MBC cases previously tested negative
for BRCA1/2 germline mutations by automated Sanger
sequencing, otherwise by a combination of screening methods
such as protein truncation test (PTT), single-strand conforma-
tion polymorphism (SSCP) analysis and denaturing high-
performance liquid chromatography (DHPLC)21 and 80 newly
recruited MBC cases with no prior BRCA1/2 mutation testing.
All MBC cases have been characterized for the main clinical-
pathologic characteristics, including: age at diagnosis, first-
degree family history (FH) and personal history (PH) of cancer,
tumor histological type, stage (TNM classification), grade, nodal
status, estrogen and progesterone receptor (ER/PR), HER2 and
Ki67/MIB1 expression, as previously described.22 For each
patient, samples of blood or DNA from peripheral blood leuko-
cytes were collected. DNA from blood samples was extracted
using ReliaPrep Blood gDNA Miniprep System (Promega,
2 Multigene panel testing in male breast cancer
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Madison, Wisconsin, USA), according to the manufacturer’s
instructions.
The study was approved by Local Ethical Committee
(Sapienza University of Rome, Prot. 669/17) and informed
consent for using information and biological samples was
obtained from all participants to the study.
Gene selection
A custom multigene panel, sequencing all exons and flanking
intronic sequences of 50 cancer-associated genes (Supporting
Information Table S1), was specifically designed. Genes were
selected to include: 1) known high- and moderate-breast and
ovarian cancer (BC/OC) susceptibility genes; 2) proposed BC/OC
susceptibility genes; 3) genes associated with BC risk identified
by Genome Wide Association Studies (GWASs); 4) genes associ-
ated with cancers frequently observed in families with MBC
(i.e. prostate, colon, pancreatic, gastrointestinal cancers and mela-
noma) and with hereditary cancer syndromes.
NGS analysis
Briefly, genomic regions were prepared in paired-end libraries
using the Nextera Rapid Capture Custom Enrichment kit
(Illumina, San Diego, California, USA), pooled and loaded
into the MiniSeq system (Illumina) for automated cluster genera-
tion, sequencing and data analysis, including variant calling. In
particular, read alignment was performed using Burrows-Wheeler
Aligner (BWA) software, while variant calling was performed
using the Genome Analysis Toolkit (GATK). In our study,
paired-end reads of 300 (150x2) base pair per sample were
obtained and a minimum of 95% of the on-target regions was
covered to a depth of at least 200x. Results were annotated and
filtered using Illumina Variant Studio software version 2.2 against
the human reference genome GRCh37.
Variant classification
Variants were classified as pathogenic/likely pathogenic (col-
lectively termed pathogenic), or benign/likely benign, based
on the published American College of Medical Genetics and
Genomics (ACMG) recommendations.23 All variants with
minor allele frequency (MAF) lower than 1% and not meeting
the criteria for benign and pathogenic or the criteria were
contradictory, were classified as Variant of Uncertain Signifi-
cance (VUS). All pathogenic variants detected by NGS were
validated by double-stranded Sanger sequencing (primer
sequences are available upon request). Variants were named
according to Human Genome Variation Society nomenclature
(HGVS, hpp://www.hgvs.org).
Statistical analysis
Case–control study, for estimation of MBC risk associated
with pathogenic variants, was performed by univariate logistic
regression analysis and MBC risk was assessed by the Odds
Ratio (OR) and its corresponding 95% confidence interval
(CI). Two independent publicly accessible datasets, the European-
American population in Exome Variant Server (EVS) dataset
(evs.gs.washingron.edu/) and the Non-Finnish European (NFE)
population in the Exome Aggregation Consortium (ExAC)
dataset (exac.broadinstitute.org/), excluding samples from The
Cancer Genome Atlas (TCGA), were used as controls for case–
control association studies.
All ExAC and EVS non-PASS variants were excluded. All
remaining loss-of-function (nonsense, frameshift, +/−1,2 splice)
variants and any missense variant defined as pathogenic in
ClinVar, were selected for analysis.
For selected genes for which significant association with high
risk of MBC emerged by case–control studies using ExAc and
EVS, the non-cancer, NFE male population in the Genome
Aggregation Database (gnomAD) dataset (gnomad.broadinstitute.
org/), was used as control for a specific case–control association
study, considering only loss-of-function variants. An additional
dataset including whole exome sequencing data of 300 Italian
healthy male individuals,21 was specifically interrogated for all the
pathogenic variants identified in MBC cases.
Clinical history and pathologic characteristics were com-
pared between pathogenic variant carriers and non-carriers.
Fisher exact test and t-test were used where appropriate. A
p value <0.05 was considered statistically significant. All statis-
tical analyses were performed with the R software (www.r-
project.org).
Results
Clinical-pathologic characteristics of MBC patients included
in the study
A total of 523 MBC patients from the ongoing Italian multicenter
study on MBC were included in our study. Clinical-pathologic
characteristics of MBC patients are provided in Table 1. Overall,
mean age at first BC diagnosis was 62 years (range 22–91 years),
87 cases (16.7%) had first-degree FH of BC/OC and 230 (44.1%)
of any cancer. PH of other cancers, mostly prostate, colorectal
and bladder cancer, was observed in 99 cases (18.9%). The
majority of male breast tumors were invasive ductal carcinomas
(83.9%), ER and PR positive (93.6% and 88.1%), HER2 negative
(80.5%) and Ki67/MIB1 low (56.5%).
Multigene panel testing in MBC patients
Multigene panel testing was performed in 523 MBCs, including
80 cases with no prior BRCA1/2 testing and 443 cases previ-
ously tested negative for BRCA1/2 germline mutations. Overall,
47 MBC patients were pathogenic variant carriers (Fig. 1).
A total of 42 pathogenic variants distributed in 16 of
50 genes, including BRCA1, BRCA2, PALB2, ATM, CHEK2,
RAD51D, RAD51C, NF1, BARD1, BLM, CASP8, FANCM,
RAD50, APC, EPCAM and MUTYH (Supporting Information
Table S2) were identified. Two patients were found to carry
two pathogenic variants, including one biallelic MUTYH car-
rier (compound heterozygous) and one RAD51C/MUTYH
carrier (double heterozygous).
Rizzolo et al. 3
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BRCA1/2 pathogenic variants were detected in 13 of the MBC
cases with no prior BRCA1/2 testing and in seven of MBC cases
previously tested negative, for a total of 20 BRCA1/2 pathogenic
variant carriers (Fig. 1). Overall, 503 MBC patients were negative
for BRCA1/2 pathogenic variants (from now on, called non-
BRCA1/2 MBCs).
Pathogenic variants in non-BRCA1/2 genes were detected in
four of the MBC cases with no prior BRCA1/2 testing and in
23 of the MBC cases previously tested negative for BRCA1/2
mutation, for a total of 27 non-BRCA1/2 MBC patients (Fig. 1).
Overall, pathogenic variants in non-BRCA1/2 genes were
detected in 5.4% (27/503) non-BRCA1/2 MBC patients.
Among the non-BRCA1/2 genes, PALB2 and ATM were
the most frequently mutated genes. In particular, of the
27 non-BRCA1/2 MBC patients, six were PALB2 carriers and
three ATM carriers (Fig. 2). Overall, among the 503 non-
BRCA1/2 MBC patients, the frequency of PALB2 pathogenic
variants was 1.2% and of ATM pathogenic variants was 0.6%.
Among the other non-BRCA1/2 BC/OC susceptibility genes
examined, pathogenic variants of BARD1, BLM, CHEK2,
FANCM and RAD51D were each detected in two (0.4%) non-
BRCA1/2 MBC patients, and pathogenic variants of CASP8, NF1,
RAD50 and RAD51C were each detected in one (0.2%) non-
BRCA1/2 MBC case (Fig. 2). One of the two CHEK2 carriers
had the CHEK2 c.1100delC variant and both the two unrelated
RAD51D carriers had the c.293delA variant (Supporting Infor-
mation Table S2).
Pathogenic variants in genes not closely related to BC pre-
disposition, including APC, EPCAM and MUTYH were also
identified in non-BRCA1/2 MBC patients (Fig. 2). In particu-
lar, two unrelated MBC cases had the APC c.3920T>A variant
and one case had biallelic MUTYH c.536A>G and c.721C>T
variants (Supporting Information Table S2). The MBC patient
with biallelic MUTYH pathogenic variants had phenotypic
manifestations of MUTYH-associated adenomatous polyposis
(MAP), whereas none of the two MBC patients with APC
c.3920T>A variant had phenotypic features associated with
familial adenomatous polyposis (FAP) or had first-degree FH
of FAP (Table 2). Monoallelic MUTYH pathogenic variants
were also detected and reported in another study.24
No pathogenic variants were found in the other genes
examined, including genes associated with hereditary cancer
syndromes, such as TP53, CDH1, PTEN and STK11.
Overall, excluding the MUTYH biallelic variant carrier with
MAP phenotype and the two APC c.3920T>A variant carriers,
due to lower associated cancer risk,11,25 pathogenic variants in
non-BRCA1/2 genes were detected in 4.8% (24/503) non-
BRCA1/2 MBC patients.
The majority of MBC cases who were carriers of patho-
genic variants in non-BRCA1/2 genes had a first-degree FH of
a combination of cancers including BC, and PH of other can-
cers in addition to BC (Table 2). As expected for MBC, the
vast majority of non-BRCA1/2 MBC cases were ER+/PR+/
HER2- and only one case, specifically a FANCM MBC case,
was a triple negative (ER-/PR-/HER2-) BC (Table 2).
A total of 120 different VUS distributed in 34 of the
50 genes analyzed (Supporting Information Table S3), were
Table 1. Clinical-pathologic characteristics of the 523 MBCs analyzed
in our study
Characteristic1 No. %
Testing history
BRCA1/2 negative 443 84.7
No prior BRCA1/2 testing 80 15.3
Mean age at diagnosis  SD (range) 62.0  11.9 (22–91)
First-degree family history of BC/OC2
Negative 435 83.3
Positive 87 16.7
First-degree family history of cancer
Negative 292 55.9
Positive 230 44.1
Personal history of cancer in addition
to BC
Negative 424 81.1
Positive 99 18.9
Tumor histotype
Invasive ductal carcinoma 375 83.9
In situ ductal carcinoma 38 8.5
Invasive lobular carcinoma 6 1.3
Medullary carcinoma 1 0.2
Other 27 6.1
TNM stage
0–1 198 54.4
2 108 29.7
3–4 58 15.9
Histologic grade
1 46 12.9
2 211 58.9
3 101 28.2
Lymph node status
Negative 229 62.7
Positive 136 37.3
ER status
Negative 26 6.4
Positive 381 93.6
PR status
Negative 48 11.9
Positive 355 88.1
HER2 status
Negative 260 80.5
Positive 63 19.5
Ki67/MIB1 status
Low 179 56.5
High 138 43.5
1Some data for each pathologic characteristic are not available.
2BC: Breast Cancer, OC: Ovarian Cancer.
4 Multigene panel testing in male breast cancer
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identified in 110 of the 523 MBC patients (21%). Overall,
10 of the 110 cases with VUS harbor also pathogenic variants.
The presence of two or more VUS was detected in 22/110 (20%)
cases, including two pathogenic variant carriers (Supporting
Information Table S4).
The majority of VUS were identified in ATM, BRCA2 and
SLX4 genes and were respectively observed in 23 (4.4%),
14 (2.7%) and 12 (2.3%) of the 523 MBCs. A significant num-
ber of VUS were also found in CHEK2 and BLM genes and
were observed in 10 (1.9%) and 8 (1.5%) of the 523 MBCs,
respectively (Supporting Information Fig. S1).
Gene-specific risk of MBC
Association between the pathogenic variants identified in
non-BRCA1/2 genes and MBC risk was assessed by case–
control studies based on sequencing results from 503 non-
BRCA1/2 MBC patients and EVS and ExAc controls
(Table 3). The cases with MUTYH biallelic variants and APC
c.3920T>A variant were not included in the analyses. Variants
in PALB2 were significantly associated with high risk of MBC
(EVS: OR 17.30; 95% CI: 4.31–69.36; p < 0.0001; ExAc: OR
11.20, 95% CI: 4.63–27.11, p < 0.0001). Significant association
also emerged for the RAD51D variants and high MBC risk
(EVS: OR 8.58; 95% CI: 1.21–61.4; p = 0.01; ExAc: OR 10.18;
95% CI: 2.22–46.58; p = 0.0002). The non-cancer NFE male
population in the gnomAD dataset was also interrogated for
the genes for which significant associations emerged. Specifi-
cally, 29,543 and 27,259 gnomAD non-cancer NFE male con-
trols were interrogated for PALB2 and RAD51D, respectively.
Both the associations between variants in PALB2 and
RAD51D and high risk of MBC were confirmed (PALB2: OR
9.63, 95% CI: 4.04–22.91, p < 0.0001; RAD51D: OR 6.04, 95%
CI: 1.4–26.11; p = 0.006). No significant associations were
observed between pathogenic variants in the other genes ana-
lyzed and MBC risk. An additional dataset including whole
exome sequencing data of 300 Italian healthy male individ-
uals, was specifically interrogated for all the pathogenic vari-
ants identified in MBC cases. None of pathogenic variants
identified in MBC cases was found in Italian healthy male
individuals.
Figure 1. Diagram showing the number of MBC patients analyzed and the number of MBC patients with pathogenic variants identified in
BRCA1/2 and non-BRCA1/2 genes.
Figure 2. Distribution and frequency of pathogenic variants identified
in the 27 non-BRCA1/2 pathogenic variant carriers. The number of
carriers is reported for each gene.
Rizzolo et al. 5
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Clinical-pathologic characteristics of MBC patients with and
without germline pathogenic variants in non-BRCA1/2 genes
Clinical-pathologic characteristics of carriers and non-carriers of
pathogenic variants in non-BRCA1/2 genes were compared
excluding the cases with MUTYH biallelic variants and APC
c.3920T>A variant. As shown in Table 4, the mean age at diag-
nosis was similar between pathogenic variant carriers (60.4 years,
range 36–85 years) and non-carriers (62 years, range
22–91 years). Pathogenic variant carriers were more likely to
have FH of cancer (p = 0.007). On the other hand, FH of BC/OC
was noticeably lacking in the majority of pathogenic variant car-
riers (22/24, 91.7%). A significant association also emerged
between carriers and PH of cancer besides BC (p = 0.0005). No
statistically significant differences emerged between carriers and
non-carriers with regards to tumor characteristics.
Discussion
We investigated genetic susceptibility to BC in men, analyzing
a large series of Italian MBC cases through a custom multi-
gene panel designed to include genes known and suggested to
be associated with increased BC/OC risk and genes associated
with cancers frequently observed in families with MBC.
Despite increasing utilization of multigene panel in diagnostic
testing for BC, to date, there is a limited number of studies
investigating the impact of mutations in genes other than
BRCA1/2 in MBC susceptibility. One study retrospectively
assessed the diagnostic yield of multigene panel testing using
data from 512 MBC patients tested for 16 genes.7 Other stud-
ies, performing multigene panel testing in MBC patients,
examined a limited number of patients, ranging from 22 to
102.8,11 In our study, we performed an extensive evaluation of
Table 2. Non-BRCA1/2 pathogenic variants detected in 27 MBC cases and clinical-pathologic characteristics of carriers
Case ID Gene Nucleotide change
Age of
onset
First-degree family
history of cancer (age)
Personal history of
other cancer (age) Tumor histotype ER PR HER2
Ki67/
MIB1
#164 APC c.3920T>A 56 Non-Hodgkin lymphoma (55) Invasive ductal + + + −
#26 APC c.3920T>A 54 Breast (40) Invasive ductal + + − −
#318 ATM c.1402_1403delAA 74 Prostate (73) Invasive ductal + + − +
#11 ATM c.1523delT 60 Breast (49, 72); Prostate (62) Colorectal (62); Lung Invasive ductal + + − −
#401 ATM c.2151_2152insT 38 Colorectal (31) Invasive ductal + + − +
#116 BARD1 c.158+1G>T 68 Breast (60); Liver (40);
Chondroma (43)
Invasive ductal + na na na
#285 BARD1 c.1765dupG 79 Colorectal (75) Kidney (63) Medullary + + − +
#388 BLM c.98+1G>C 63 Invasive ductal + + − +
#476 BLM c.1828_1829insT 60 Prostate (71,78) Invasive ductal + + − −
#354 CASP8 c.280C>T 57 Lung (75) Invasive ductal na na na na
#199 CHEK2 c.1100delC 36 Prostate (70) Invasive ductal + + + +
#363 CHEK2 c.1427C>T 72 Liposarcoma (49) Melanoma (66) Invasive ductal + + − −
#132 EPCAM c.13C>T 52 Prostate (67) Invasive ductal + + − −
#56 FANCM c.1432C>T 41 Melanoma (81) In situ ductal − − − na
#163 FANCM c.1972C>T 55 Breast (46); Colorectal (23) Skin (58) Other (intracystic
papillary)
+ + na −
#2271 MUTYH c.536A>G; c.721C>T 51 Melanoma (26) Colorectal (41) Invasive ductal + + − −
#492 NF1 c.574C>T 54 Breast (60); Condrosarcoma (58);
Non-Hodgkin lymphoma (55)
Invasive ductal − + na −
#141 PALB2 c.419delA 76 Male breast (66);
Glioma (48); Gastric (74)
Melanoma (65) Invasive ductal + + − +
#20 PALB2 c.1140_1143delTCTT 38 Lung (69); Paget’s Disease (30) Invasive ductal + + − +
#523 PALB2 c.1984A>T 60 Breast (80) Lung (66);
Prostate (67)
Invasive ductal − + na −
#405 PALB2 c.2167_2168delAT 85 Breast (61); Gastric (60);
Melanoma (73)
Invasive ductal + + − +
#232 PALB2 c.2257C>T 44 Breast (79); Colorectal (71) Invasive ductal + + + −
#47 PALB2 c.3332delC 70 Breast (34, 45, 63) Invasive ductal na na na na
#409 RAD50 c.1238_1241delAACT 46 Invasive ductal + + − −
#4783 RAD51C c.905-2_905-1delAG 82 Colorectal (50) Invasive ductal + + − −
#195 RAD51D c.293delA 62 Tongue (56) Invasive ductal + + − +
#432 RAD51D c.293delA 77 Breast (52); Laringeal (50) Sarcoma (77) Invasive ductal + + na +
1Compound heterozygote.
2NF1 (Neurofibromatosis type 1) patient.
3Double heterozygote: RAD51C/MUTYH c.536A>G (p.Tyr179Cys).
na: not available; +: positive; −: negative.
6 Multigene panel testing in male breast cancer
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a large multigene panel, including 50 cancer-associated genes,
in a well-characterized series of 523 MBC cases from a single
Country, making this the largest collection reported to date of
MBC patients all undergoing a comprehensive multigene
panel testing. Furthermore, compared to previous studies, our
study benefits from a large series of MBC cases with an accu-
rate and extensive characterization for clinical and pathologi-
cal data collected by a geneticist and validated by relevant
sources, mainly local cancer and mortality registries.
As expected, BRCA1/2 pathogenic variants were the most
frequent mutations found in MBC patients with no prior
BRCA1/2 testing (16.3%). In particular, BRCA2 pathogenic
variants were identified in 12.5% of the cases, thus confirming
the role of BRCA2 as the key gene associated with increased
risk of developing BC in men. BRCA1/2 pathogenic variants
were also detected in 1.6% of MBC cases previously tested neg-
ative for BRCA1/2. Specifically, all the cases detected with
BRCA1/2 pathogenic variants by NGS and previously tested
and labeled negative, had been analyzed by PTT, SSCP and
DHPLC. These results show that these screening methods may
lead to false negatives and that NGS is more sensitive in detect-
ing BRCA1/2 sequence variants. Thus, our results highlight the
need to re-assess patients using new NGS technologies.26
Among non-BRCA1/2 genes a significant role of PALB2 in
MBC susceptibility emerged. We have previously shown that
PALB2 plays a relevant role in high-risk, non-BRCA1/2 MBC
cases.27 In the present study, more than 1% of non-BRCA1/2
MBC cases, unselected for FH of BC/OC had a germline PALB2
pathogenic variant. PALB2 pathogenic variants were frequently
found in MBC patients with first-degree FH of cancers in
addition to BC, suggesting that hereditary MBC does not neces-
sarily appear in BC/OC families only and that MBC may be
instrumental in the identification of PALB2-like families. In
our study, we also showed that pathogenic variants in PALB2
were associated with a high risk of MBC, ranging from 9.63 to
17.30-fold increased, according to the datasets used as controls.
Thus, the estimated MBC risk of PALB2 pathogenic variants in
our study population was higher than those previously reported,
ranging from 6.60 to 8-fold increased risk.7,28 Overall, these
results reinforce previous evidence and extend the role of PALB2
in MBC susceptibility, drawing attention to its relevance in MBC
genetic testing.
ATM was the second most frequently altered gene in our
MBC series with pathogenic variants identified in 0.6% of
non-BRCA1/2 MBC cases. These results are in line with recent
studies reporting heterozygous ATM variants in MBC with a
frequency ranging from 0.5% to 1.96%.7,8,11 In our study, no
significant association between ATM pathogenic variants and
increased MBC risk emerged, in agreement with previous
data.7 Larger collaborative studies are needed to further esti-
mate BC risk in men with ATM variants.
CHEK2 pathogenic variants were found in 0.4% of our MBC
cases. Germline mutations in CHEK2, particularly, the CHEK2
c.1100delC variant, increase the risk of developing MBC.29 In our
study, we found a lower frequency of CHEK2 pathogenic variants
compared to those reported in other MBC series, ranging from
1% to 9%.7,8,11,29–31 In particular, the CHEK2 c.1100delC variant
was detected in only one case of our MBC series (0.2%). No sig-
nificant association between CHEK2 pathogenic variants and
increased risk of MBC was observed. Overall, these results sup-
port our previous data indicating that CHEK2, and in particular
the CHEK2 c.1100delC variant, does not play a relevant role in
BC genetic predisposition in the Italian population32 and, in par-
ticular, in MBC.33
Table 3. Analysis of MBC risk associated with pathogenic variants in panel genes
MBC cases, No. 503 EVS controls, No. 4,300 ExAC controls MBC Risk1
Gene
Mutated
No.
Mutation
frequency %
Mutated
No.
Mutation
frequency %
Mutated
No.
Total
No.
Mutation
frequency %
MBC vs. EVS
OR (95% CI), p2
MBC vs. ExAC
OR (95% CI), p2
ATM 3 0.6 12 0.28 92 26,868 0.34 2.14 (0.6–7.6), 0.2 1.75 (0.55–5.5), 0.3
BARD1 1 0.2 - - 21 26,504 0.08 - 2.50 (0.34–18.7), 0.4
BLM 2 0.4 12 0.28 47 26,470 0.18 1.43 (0.32–6.39), 0.6 2.20 (0.54–9.27), 0.3
CASP8 1 0.2 3 0.07 7 27,081 0.025 2.85 (0.3–27.48), 0.3 7.70 (0.95–62.7), 0.02
CHEK2 2 0.4 21 0.49 164 25,406 0.64 0.81 (0.19–3.48), 0.8 0.60 (0.15–2.48), 0.5
EPCAM 1 0.2 2 0.05 14 25,154 0.055 4.28 (0.39–47.3), 0.2 3.60 (0.5–27.26), 0.2
FANCM 2 0.4 18 0.42 174 26,479 0.66 1.07 (0.25–4.6), 0.9 0.60 (0.15–2.46), 0.5
NF1 1 0.2 4 0.09 25 26,501 0.09 2.14 (0.24–19.2), 0.5 2.11 (0.29–15.6), 0.5
PALB2 6 1.2 3 0.07 29 26,941 0.10 17.30 (4.31–69.36),
<0.0001
11.20 (4.63–27.11),
<0.0001
RAD50 1 0.2 12 0.28 52 26,830 0.19 0.70 (0.09–5.49), 0.7 1.03 (0.14–7.44), 0.1
RAD51C 1 0.2 - - 31 26,774 0.11 - 1.72 (0.23–12.6), 0.6
RAD51D 2 0.4 2 0.04 10 25,309 0.04 8.58 (1.21–61.4),
0.01
10.18 (2.22–46.58),
0.0002
1Cancer risk was assessed by the Odds Ratio (OR) and its corresponding 95% confidence interval (CI), calculated by univariate logistic regression
analysis.
2p Value <0.05 in bold text.
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Pathogenic variants in RAD51C and RAD51D were also
detected in our study. To the best of our knowledge, this is the
first study reporting germline pathogenic variants of these two
genes in MBC cases. To date, the role of RAD51C and RAD51D
as moderate OC susceptibility genes is well-established, whereas
their contribution to BC risk is less clear.9,18 Interestingly,
we found the same variant of RAD51D (c.293delA) in two
unrelated cases and indication of an association with MBC
Table 4. Clinical-pathologic characteristics of non-BRCA1/2 MBCs: comparison between non-BRCA1/2 pathogenic variant carriers and non-
carriers
Characteristic 1
Non-BRCA1/2 pathogenic variant carriers (No. 24)2 non-carriers (No. 476)
p-value4
No. % No. %
Mean age at diagnosis  SD (range) 60.4  14.7 (36–85) 62.0  11.8 (22–91) 0.6
First-degree family history of BC/OC3
Negative 22 91.7 400 84.2
Positive 2 8.3 75 15.8 0.3
First-degree family history of cancer
Negative 7 29.2 272 57.3
Positive 17 70.8 203 42.7 0.007
Personal history of cancer in addition to BC
Negative 13 54.2 393 82.6
Positive 11 45.8 83 17.4 0.0005
Tumor histotype
Invasive ductal carcinoma 21 87.4 334 83.0
In situ ductal carcinoma 1 4.2 36 9.0
Invasive lobular carcinoma 0 - 6 1.5
Medullary carcinoma 1 4.2 0 -
Other 1 4.2 26 6.5 0.1
TNM stage
0–1 7 50.0 184 55.3
2 5 35.7 95 28.5
3–4 2 14.3 54 16.2 0.9
Histologic grade
1 2 11.8 43 13.2
2 10 58.8 196 60.3
3 5 29.4 86 26.5 0.9
Lymph node status
Negative 12 70.6 209 63.0
Positive 5 29.4 123 37.0 0.6
ER status
Negative 3 13.6 21 5.8
Positive 19 86.4 344 94.2 0.1
PR status
Negative 1 4.8 43 11.9
Positive 20 95.2 319 88.1 0.5
HER2 status
Negative 15 88.2 233 80.3
Positive 2 11.8 57 19.7 0.5
Ki67/MIB1 status
Low 10 50.0 163 58.0
High 10 50.0 118 42.0 0.5
1Some data for each pathologic characteristic are not available.
2APC variant carriers (No. 2) and MUTYH biallelic variant carrier (No. 1) were excluded from the analysis.
3BC: Breast Cancer, OC: Ovarian Cancer.
4p Value <0.05 in bold text.
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risk emerged with an estimated risk increased from 6.04 to
10.80-fold, according to the datasets used as controls. Over-
all, our findings may add evidence on a possible role of
RAD51D as BC susceptibility gene.14
A pathogenic variant in NF1 was found in one MBC
patient. The relationship between neurofibromatosis type
1 (NF1) and BC in women is known,34 by contrast, the
concurrent presentation of NF1 and BC in men is a very
rare phenomenon. To the best of our knowledge, only five
other cases of NF1 and MBC have been reported.35–38
Thus, our results emphasize the need to perform further
studies to elucidate the link between these two rare dis-
eases, as it could improve the clinical management of
patients affected by NF1. Moreover, there is evidence
suggesting that pathogenic variants in NF1 may confer
resistance to antiestrogen treatment in BC.39 This can be
particularly relevant in clinical management of men with BC
as the vast majority of male breast tumors are hormone
receptor-positive,22,40 therefore MBC patients often receive
antiestrogen therapy.
Pathogenic variants in genes proposed as BC susceptibility
genes, including BARD1, BLM, CASP8, FANCM and
RAD50,9,41,42 were found in our MBC series with a frequency
ranging from 0.2% to 0.4%. To date, the penetrance and the
clinical spectrum associated with these genes are not well-
characterized11 and, with the exception of FANCM,21 the
impact of these genes in MBC predisposition remains largely
unknown. Our findings may suggest a possible role of these
genes in MBC susceptibility, however, further studies are
needed to add evidence on their role in BC.
The majority of pathogenic variants identified in our study
were in genes belonging to the homologous recombination
(HR) mechanism functionally linked to BRCA1/2.9 There is
evidence that germline mutations in genes involved in HR
mechanism, such as PALB2, ATM and RAD51C, are associ-
ated with sensitivity to PARP inhibitors (PARPi).43,44 Overall,
our results highlight the central role of HR pathway in MBC
susceptibility, with a possible impact on therapeutic manage-
ment of MBC patients.
Pathogenic variants in genes considered not closely related
to BC predisposition, including APC, EPCAM and MUTYH,
were also detected in our MBC cases. We identified the well-
known colorectal cancer-associated APC c.3920T>A (p.
Ile1307Lys) variant45 in two unrelated MBC cases with no
personal and family history of FAP syndrome. This variant
has been reported as a candidate low penetrance BC risk gene
or genetic modifier in BRCA1/2 cases.13,25,46 Further studies
are needed to elucidate if the APC p.Ile1307Lys variant can
play a role as low penetrance allele in MBC susceptibility. We
also identified biallelic pathogenic variants of MUTYH in a
MBC patient with phenotypic manifestation of MAP. To our
knowledge, this is the second MBC case reported associated to
MAP syndrome.47 These findings suggest that MBC may be
part of the tumor spectrum associated with MAP syndrome,
with implication in clinical management of the patients and
their relatives.
In agreement with other reports on multigene panel testing
in MBC,7,8 in our study, no pathogenic variants were found in
genes associated with hereditary cancer syndromes, including
TP53. TP53 pathogenic variants have been reported among
women with BC, who have had panel testing, with a frequency
ranging from 0.3% to 1.9%.13,17,48 These findings, while indi-
cating that TP53 may not play a significant role in MBC, sug-
gest that men with clinical history suggestive of Li-Fraumeni
syndrome would have had TP53 testing first49 instead of mul-
tigene panel testing for BC, as BC often appears at older age
in men than in women.
Overall, we found pathogenic variants only in a fraction of
the genes analyzed, some of which not previously associated
with BC risk. These results indicate that the identification of
the more appropriate genes for the genomic screening of
MBC patients is essential in order to develop a comprehensive
and specific BC susceptibility panel.
In order to examine predictors of identifying pathogenic var-
iants in non-BRCA1/2 genes, we compared clinical-pathologic
characteristics between pathogenic variant carriers and non-
carriers and showed that carriers were more likely to have PH
of other cancers in addition to BC and FH of cancer, compared
to non-carriers. These findings suggest that multigene testing
approach may benefit from appropriately selected patients, espe-
cially those with a personal or family history of cancer, allowing
for testing at-risk families. The association between the presence
of non-BRCA1/2 pathogenic variants and PH and FH of cancer
observed in our study needs to be further investigated in larger
studies, as more intensive surveillance might be justified in car-
riers with important implications for clinical management of
MBC patients and their family members.
The identification of non-BRCA1/2 pathogenic variants
in MBC patients could guide cancer surveillance and pre-
vention recommendations both for the affected men and
their relatives. To date, National Comprehensive Cancer
Network (NCCN) guidelines are only available for the clini-
cal management of men with BRCA1/2 germline pathogenic
variants.50 On the other hand, NCCN guidelines are also
available for women with germline pathogenic variants in
non-BRCA1/2 genes, such as PALB2, ATM, CHEK2 and
NF1.50 Our results indicate the need to perform further col-
laborative studies in non-BRCA1/2 MBCs in order to pro-
vide data that may be instrumental in establishing
guidelines for the clinical management of men carriers of
pathogenic variants in these genes.
Although a large series of MBC cases was analyzed, the
power of our study may be insufficient in order to identify
smaller risk effects. Moreover, information on tumor character-
istics was not available for all cases. Thus, some associations
may be underestimated. Larger-scale collaborative multicenter
studies are needed to investigate any possible association with
rarer variants and to provide a more precise MBC risk estimate.
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In conclusion, results from our study support a central role
of PALB2 in MBC susceptibility and confirm a low impact of
CHEK2 on MBC predisposition in the Italian population. Our
findings also highlight the importance of NGS panels to iden-
tify genes involved in MBC susceptibility and to better define
the fraction of MBC cases due to genetic predisposition.
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